CHEK - Check-Cap Ltd.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Isfiya,
Israel
Type: Equity
CHEK price evolution
CHEK
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $24.86 | $28.77 | $33.26 | $38.5 |
| Long term investments | ||||
| Property, plant & equipment | $0.16 | $0.26 | $0.47 | $2.81 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $25.02 | $29.03 | $33.73 | $41.31 |
| Current liabilities | ||||
| Accounts payable | $0.14 | $0.11 | $0.78 | $1.18 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.33 | $1.64 | $3.54 | $3.56 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1.33 | $1.64 | $3.54 | $4.29 |
| Shareholders' equity | ||||
| Retained earnings | -$144.86 | -$141.2 | -$138.61 | -$131.74 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $26.46 | $7.7 | ||
| Short term investments | $25.12 | $10.09 | ||
| Net receivables | $0.21 | $0.14 | ||
| Inventory | ||||
| Total current assets | $24.86 | $42.63 | $52.75 | $18.42 |
| Long term investments | ||||
| Property, plant & equipment | $0.16 | $2.81 | $2.91 | $1.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.22 | |||
| Total investments | ||||
| Total assets | $25.02 | $45.44 | $55.66 | $19.64 |
| Current liabilities | ||||
| Accounts payable | $0.14 | $0.95 | $1.05 | $0.86 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.33 | $3.41 | $4.04 | $2.98 |
| Long term debt | ||||
| Total noncurrent liabilities | $0.28 | |||
| Total debt | ||||
| Total liabilities | $1.33 | $4.13 | $4.97 | $3.26 |
| Shareholders' equity | ||||
| Retained earnings | -$144.86 | -$127.29 | -$108.19 | -$90.98 |
| Other shareholder equity | ||||
| Total shareholder equity | $50.69 | $16.38 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $4.08 | $2.86 | $6.06 | $4.85 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.43 | $0.55 | $0.41 | |
| Net income | ||||
| Net income | -$3.66 | -$2.59 | -$6.88 | -$4.44 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $10.01 | |||
| Selling, general & administrative | $3.92 | |||
| Total operating expenses | $17.86 | $20.03 | $13.93 | |
| Operating income | -$13.93 | |||
| Income from continuing operations | ||||
| EBIT | -$13.93 | |||
| Income tax expense | ||||
| Interest expense | $1.63 | $0.89 | ||
| Net income | ||||
| Net income | -$17.57 | -$19.11 | -$13.85 | |
| Income (for common shares) | -$13.85 | |||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $21.36 | $4.5 | $7.99 | $17 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | ||||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $4.4 | $0.91 | -$1.84 | $12.38 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$17.2 | -$13.85 | ||
| Operating activities | ||||
| Depreciation | $0.2 | $0.15 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$16.26 | -$13.11 | ||
| Investing activities | ||||
| Capital expenditures | -$1.01 | -$0.38 | ||
| Investments | -$15 | -$10.07 | ||
| Total cash flows from investing | $21.36 | -$12.51 | -$16.01 | -$10.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $8.85 | $51.02 | $23.58 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $4.4 | -$22.37 | $18.75 | $0.02 |
News
Fundamentals
| Market cap | $10.47M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 5.85M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$17.57M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.60 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.00 |
|---|---|
| ROA | -54.44% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 18.69 |
| Quick ratio | N/A |